Vaccination Response in Tecfidera-Treated Versus Interferon-Treated Participants With Relapsing Forms of Multiple Sclerosis.
Completed
Biogen
Phase 2
2015-02-28
Primary objective is to evaluate the immune response to vaccination with tetanus diphtheria
toxoids vaccine (Td) in participants with relapsing forms of Multiple Sclerosis (MS) who have
been treated with Tecfidera (BG00012) versus those treated with non pegylated interferon
(IFN).
Secondary objective is to evaluate the immune response to vaccination with 23-valent
pneumococcal polysaccharide vaccine (PPSV23) [a mostly T cell-independent humoral response]
and meningococcal polysaccharide diphtheria conjugate vaccine, quadrivalent (MCV4) [T
cell-dependent neoantigen response].
IDH1 Peptide Vaccine for Recurrent Grade II Glioma
Active, not recruiting
Gary Archer Ph.D.
Phase 1
2016-01-28
Potential subjects with progressive Grade II primary brain tumor that have IDH1 positive
testing from the primary tumor (initial diagnosis) will be offered this treatment study in
order to test the safety of the PEPIDH1M vaccine in combination with standard chemotherapy
(temozolomide).
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
